The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
The gut-kidney axis: indoxyl sulfate, p-cresyl sulfate and CKD progression
Open accessAbstract
‘The special position assigned to urea appears to date from the time at which urea could not be formed synthetically and was believed to arise only in living matter. Now that urea is formed artificially, it has been robbed of much of its mystery.’ (A. R. Cushny, The secretion of urine, 1917) The fundamental insights into uraemic toxicity have evolved little since publication of the classical monograph by Cushny nearly a century ago [1]. Organic metabolites are still thought to substantially contribute to uremia (albeit urea might not be the culprit), yet evidence unequivocally demonstrating toxicity of any single uraemic constituent is lacking [2]. To advance research in uraemic toxicity, the European Toxin work group (EUTox) developed a classification of uraemic blood constituents according to characteristics that affect their removal during dialysis [3]. Besides small water-soluble molecules (e.g. urea and creatinine) and peptides/proteins (e.g. β2-microglobulin), they identified a group of solutes that circulate in equilibrium between free solute versus bound to carrier proteins. Tight protein binding severely limits solute clearances by dialysis [4]. Intriguingly, a substantial number of these so-called protein-bound uraemic retention solutes originate from protein fermentation in the large intestine, including p-cresyl sulfate and indoxyl sulfate [5]. Recently, several groups demonstrated direct associations between p-cresol, mainly reflecting p-cresyl sulfate, and overall mortality and cardiovascular disease in end-stage renal disease [6,7] and in chronic kidney disease (CKD) [8,9]. Likewise, direct associations between indoxyl sulfate and overall mortality and cardiovascular disease were reported [10]. While indoxyl sulfate and p-cresyl sulfate are frequently thought of as independent uraemic retention solutes, they share common ground. First, as mentioned before, p-cresyl sulfate and indoxyl sulfate both originate from bacterial protein fermentation in the large intestine. Colonic microbiota degrade tryptophan to indole. Further hydroxylation results in 3-hydroxy-indole, the majority of which is sulfonated to indoxyl sulfate. In parallel, fermentation of tyrosine results in p-cresol and ultimately p-cresyl sulfate [11]. Recently, we reported on sulfate conjugation of p-cresol in CKD [12,13]. Second, most p-cresyl sulfate and indoxyl sulfate circulates noncovalently bound to albumin and competes for the same albumin-binding sites (Sudlow site II) [14] (Figure 1). Indoxyl sulfate and p-cresyl sulfate are interchangeable marker molecules to study behaviour of protein-bound solutes during dialysis [15]. The colon is responsible for salvage of energy and possibly nitrogen from carbohydrate (CHO) and protein not digested in the upper gastrointestinal tract. Fermentation of the amino acids tyrosine and tryptophan by intestinal microbiota generates p-cresyl and indole, respectively. After absorption, these are further metabolized to generate p-cresyl sulfate and p-indoxyl sulfate. Indoxyl sulfate and p-cresyl sulfate circulate in equilibrium between a free solute fraction and a fraction bound to serum proteins. The best-characterized binding site is albumin Sudlow site II, for which indoxyl sulfate and p-cresyl sulfate are competitive binding inhibitors. In this issue of Nephrology Dialysis Transplantation, Wu et al. demonstrate that serum indoxyl sulfate is associated with progression of CKD, confirming previous findings. Niwa et al. first advanced the hypothesis that accumulation of indoxyl sulfate accelerates glomerular sclerosis and progression of kidney disease [16,17]. Animal and small-scale human studies on CKD patients suggested retardation of CKD progression by adsorption of indole in the large intestine [18,19]. Intriguingly, Wu et al. equally demonstrate that p-cresyl sulfate is associated with CKD progression. Does this indicate that indoxyl sulfate and p-cresyl sulfate be considered equally valid markers for CKD progression? This illustrates one of the key problems we are faced with when investigating uremia. One of the hallmarks of uraemic retention solutes is that they all move more or less in the same direction. When glomerular filtration rate falls, concentrations of the uraemic retention solutes we measure, and most likely a host of solutes that we are not aware of, all rise. Indeed, in the current study, Wu et al. observed a moderate correlation between indoxyl sulfate and estimated glomerular filtration rate (eGFR) (r −0.72, P < 0.001), between p-cresyl sulfate and eGFR (r −0.64, P < 0.001) and between indoxyl sulfate and p-cresyl sulfate (r 0.66, P < 0.001). From a statistical point of view, if nominally related measures actually quantify the same phenomenon, then they are redundant, i.e. collinear. This might lead us to conclude that indoxyl sulfate and p-cresyl sulfate are plain markers of kidney function. The strongpoint of the study by Wu et al. is that they went to great length to
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites
Wikoff, W. R., Anfora, A. T., Liu, J., Schultz, P. G., Lesley, S. A., Peters, E. C., & Siuzdak, G. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812874106 · Cited by 2,677
The Journal of Laboratory and Clinical Medicine
(2003) · Journal of Laboratory and Clinical Medicine · doi:10.1016/s0022-2143(03)00127-6 · Cited by 1,767
Review on uremic toxins: Classification, concentration, and interindividual variability
Vanholder, R., For the European Uremic Toxin Work Group (EUTox), De Smet, R., Glorieux, G., Argilés, A., Baurmeister, U., Brunet, P., Clark, W., Cohen, G., De Deyn, P. P., et al. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00924.x · Cited by 1,720
Barreto, F. C., Barreto, D. V., Liabeuf, S., Meert, N., Glorieux, G., Temmar, M., Choukroun, G., Vanholder, R., & Massy, Z. A. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03980609 · Cited by 929
Meyer, T. W., & Hostetter, T. H. (2007) · New England Journal of Medicine · doi:10.1056/nejmra071313 · Cited by 458
Uremic toxins originating from colonic microbial metabolism
Evenepoel, P., Meijers, B. K. I., Bammens, B. R. M., & Verbeke, K. (2009) · Kidney International · doi:10.1038/ki.2009.402 · Cited by 445
Self-citationLiabeuf, S., Barreto, D. V., Barreto, F. C., Meert, N., Glorieux, G., Schepers, E., Temmar, M., Choukroun, G., Vanholder, R., Massy, Z. A., et al. (2010) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp592 · Cited by 431
Indoxyl sulfate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis.
Niwa, T., & Ise, M. (1994) · PubMed · Cited by 410
Bammens, B., Evenepoel, P., Keuleers, H., Verbeke, K., & Vanrenterghem, Y. (2006) · Kidney International · doi:10.1038/sj.ki.5000115 · Cited by 388
Self-citationp-Cresol and Cardiovascular Risk in Mild-to-Moderate Kidney Disease
Meijers, B. K. I., Claes, K., Bammens, B., de Loor, H., Viaene, L., Verbeke, K., Kuypers, D., Vanrenterghem, Y., & Evenepoel, P. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.07971109 · Cited by 316
Self-citation
Cited by
Oliphant, K., & Allen-Vercoe, E. (2019) · Microbiome · doi:10.1186/s40168-019-0704-8 · Cited by 1,327
Interplay between the human gut microbiome and host metabolism
Visconti, A., Le Roy, C. I., Rosa, F., Rossi, N., Martin, T. C., Mohney, R. P., Li, W., de Rinaldis, E., Bell, J. T., Venter, J. C., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12476-z · Cited by 782
Fröhlich, E. E., Farzi, A., Mayerhofer, R., Reichmann, F., Jačan, A., Wagner, B., Zinser, E., Bordag, N., Magnes, C., Fröhlich, E., et al. (2016) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2016.02.020 · Cited by 720
Inflammation-Related Mechanisms in Chronic Kidney Disease Prediction, Progression, and Outcome
Mihai, S., Codrici, E., Popescu, I. D., Enciu, A.-M., Albulescu, L., Necula, L. G., Mambet, C., Anton, G., & Tanase, C. (2018) · Journal of Immunology Research · doi:10.1155/2018/2180373 · Cited by 673
Role of the Gut Microbiome in Uremia: A Potential Therapeutic Target
Ramezani, A., Massy, Z. A., Meijers, B., Evenepoel, P., Vanholder, R., & Raj, D. S. (2016) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.09.027 · Cited by 394
Self-citation
Metadata
- Authors
- Meijers, B. K. I., & Evenepoel, P.
- Venue
- Nephrology Dialysis Transplantation
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-02-22
- Volume
- 26
- Issue
- 3
- Pages
- 759-761
- ISSN
- 0931-0509 (ISSN-L)
- 1460-2385
- OpenAlex
- W2002138274
- Cited by
- 328
- References
- 25
- FWCI
- 6.36
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The gut-kidney axis: indoxyl sulfate, p-cresyl sulfate and CKD progression. https://app.cochat.ai/papers/10.1093/ndt/gfq818
- The paper
- Meijers, B. K. I., & Evenepoel, P. (2011). The gut-kidney axis: indoxyl sulfate, p-cresyl sulfate and CKD progression. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfq818
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.